Currently, CD19-targeted therapy is largely based on antibody technology, in that the targeting ligand for recognizing tumor cells is either an antibody or part of an antibody, such as single-chain variable fragments (scFv) of antibody in case of CAR-T therapy. Here, CD19 is linked to neoplasm.